612 related articles for article (PubMed ID: 33934609)
1. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
Baik AH; Oluwole OO; Johnson DB; Shah N; Salem JE; Tsai KK; Moslehi JJ
Circ Res; 2021 May; 128(11):1780-1801. PubMed ID: 33934609
[TBL] [Abstract][Full Text] [Related]
2. The Cardiovascular Complications of Chimeric Antigen Receptor T Cell Therapy.
Jamal FA; Khaled SK
Curr Hematol Malig Rep; 2020 Apr; 15(2):130-132. PubMed ID: 32016789
[TBL] [Abstract][Full Text] [Related]
3. Neurological Immunotoxicity from Cancer Treatment.
Wesley SF; Haggiagi A; Thakur KT; De Jager PL
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201529
[TBL] [Abstract][Full Text] [Related]
4. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
[TBL] [Abstract][Full Text] [Related]
5. Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management.
Kovac MB; Seruga B
Radiol Oncol; 2024 Jun; 58(2):170-178. PubMed ID: 38613842
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular toxicity of immune therapies for cancer.
Palaskas NL; Ali HJ; Koutroumpakis E; Ganatra S; Deswal A
BMJ; 2024 May; 385():e075859. PubMed ID: 38749554
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicities of novel cancer immunotherapies.
Stein-Merlob AF; Rothberg MV; Ribas A; Yang EH
Heart; 2021 Nov; 107(21):1694-1703. PubMed ID: 33722826
[TBL] [Abstract][Full Text] [Related]
8. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies.
Stein-Merlob AF; Rothberg MV; Holman P; Yang EH
Curr Cardiol Rep; 2021 Jan; 23(3):11. PubMed ID: 33483873
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
Kotch C; Barrett D; Teachey DT
Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
[No Abstract] [Full Text] [Related]
11. Acute Kidney Injury in Cancer Immunotherapy Recipients.
Joseph A; Lafarge A; Azoulay E; Zafrani L
Cells; 2022 Dec; 11(24):. PubMed ID: 36552755
[TBL] [Abstract][Full Text] [Related]
12. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
Siegler EL; Kenderian SS
Front Immunol; 2020; 11():1973. PubMed ID: 32983132
[TBL] [Abstract][Full Text] [Related]
13. Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials.
Stewart MD; McCall B; Pasquini M; Yang AS; Britten CD; Chuk M; De Claro RA; George B; Gormley N; Horowitz MM; Kowack E; McCoy C; Morrow PK; Okoye E; Ricafort R; Rossi J; Sharon E; Theoret M; Vegni F; Yu T; Allen J
Cytotherapy; 2022 Jul; 24(7):742-749. PubMed ID: 35219582
[TBL] [Abstract][Full Text] [Related]
14. Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures.
Shah D; Soper B; Shopland L
Front Immunol; 2023; 14():1190379. PubMed ID: 37304291
[TBL] [Abstract][Full Text] [Related]
15. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
16. Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond.
Patel M; Hudson O; Han J; Kondapalli L; Arora G; Hawi R; Andrikopoulou E; Estes C; Johnson AM; Lenneman C
Curr Treat Options Oncol; 2023 Nov; 24(11):1489-1503. PubMed ID: 37624557
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
Baik AH; Tsai KK; Oh DY; Aras MA
Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402
[TBL] [Abstract][Full Text] [Related]
19. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
[TBL] [Abstract][Full Text] [Related]
20. Supportive care measures for bispecific T-cell engager therapies in haematological malignancies.
Chen LY; Kothari J
Curr Opin Support Palliat Care; 2024 Jun; 18(2):92-99. PubMed ID: 38652455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]